Chris Francis Sells 9,375 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 9,375 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $16.03, for a total transaction of $150,281.25. Following the completion of the sale, the insider owned 25,000 shares of the company’s stock, valued at $400,750. This trade represents a 27.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Chris Francis also recently made the following trade(s):

• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The stock was sold at an average price of $14.57, for a total transaction of $6,425,821.67.

WAVE Life Sciences Price Performance

WAVE Life Sciences stock traded up $0.15 during mid-day trading on Tuesday, reaching $15.15. The company had a trading volume of 15,031,043 shares, compared to its average volume of 6,388,680. The stock’s 50-day simple moving average is $11.78 and its 200-day simple moving average is $9.26. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73. The company has a market capitalization of $2.53 billion, a P/E ratio of -20.20 and a beta of -1.82.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $9.85 million. On average, equities analysts forecast that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on WVE shares. B. Riley lifted their price target on WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Leerink Partners reiterated an “outperform” rating on shares of WAVE Life Sciences in a research report on Monday, December 8th. UBS Group set a $32.00 price objective on shares of WAVE Life Sciences in a research note on Tuesday, December 16th. HC Wainwright upped their target price on WAVE Life Sciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $21.00 target price on shares of WAVE Life Sciences in a report on Monday, December 8th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.67.

Institutional Trading of WAVE Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in WVE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in WAVE Life Sciences by 9.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after acquiring an additional 4,957 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of WAVE Life Sciences by 3.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after purchasing an additional 20,624 shares during the period. Ascent Group LLC purchased a new position in shares of WAVE Life Sciences in the 1st quarter worth about $83,000. Strs Ohio acquired a new position in shares of WAVE Life Sciences in the 1st quarter valued at about $406,000. Finally, Rhumbline Advisers grew its holdings in shares of WAVE Life Sciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 132,700 shares of the company’s stock worth $1,072,000 after purchasing an additional 7,860 shares during the period. 89.73% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.